Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-16 02:02 UTC

BIOMED PULSE

August 16, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has become the largest Ebola outbreak ever recorded in the country, with transmission intensifying and geographic spread accelerating as of August 14, 2026. [1] The overall mood is urgent on the outbreak front and cautiously productive on longevity science, with new data on senescence, statin deprescribing, and metformin in older adults. [2] [3]

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA (DRC) - LARGEST OUTBREAK ON RECORD

  • As of August 14, 2026, WHO's Disease Outbreak News (DON-615) describes the DRC Bundibugyo virus disease outbreak as "in a phase of intense transmission" and now the largest Ebola outbreak ever reported in the country. [1]
  • The outbreak began in Mongbwalu Health Zone, Ituri Province, first detected May 5, 2026, and has since expanded to multiple provinces with sustained community transmission. [4] [1]
  • Cross-border spread into Uganda had been confirmed as of earlier updates, with cumulative confirmed cases reaching 2,124 and 828 deaths as of July 15, 2026 — figures have continued climbing since. [5]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and enhanced airport screening at Washington-Dulles and Atlanta Hartsfield-Jackson airports was activated in late May. [6] [7]
  • The Bundibugyo species (distinct from the better-known Zaire Ebola species) causes hemorrhagic fever with a case fatality ratio historically around 25-35%; the current DRC outbreak's confirmed case fatality is tracking above that range. [8] [9]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP

  • WHO's fifth Disease Outbreak News posting (DON-611, July 2, 2026) confirmed the outbreak is linked to Andes hantavirus (ANDV) transmitted aboard the cruise ship M/V Hondius. [10]
  • The outbreak was first notified to WHO on May 2, 2026; the ship carried 147 passengers and crew at the time of initial detection, with 34 passengers and crew having already disembarked.
  • As of the May 13 WHO report, two additional confirmed cases were identified since the previous DON, bringing the case count beyond the original seven (two confirmed, five suspected).
  • CDC provided updated hantavirus response transcripts through June 24, 2026, indicating continued monitoring of contacts across multiple countries.
  • Andes hantavirus causes hantavirus pulmonary syndrome with a case fatality ratio approaching 35-40%; it is uniquely the only hantavirus strain with documented person-to-person transmission.

CYCLOSPORA - TACO BELL LETTUCE OUTBREAK

  • Shredded iceberg lettuce served at Taco Bell locations was confirmed by CDC as the source of a Cyclospora cayetanensis outbreak affecting five states as of July 17, 2026, with 1,644 people ill.
  • The outbreak subsequently expanded to four additional states as of July 24, 2026.
  • CDC issued a transcript update on its cyclosporiasis response on July 14, 2026, describing active field investigation.

SALMONELLA - JALAPEÑOS

  • CDC issued a food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.

NIPAH VIRUS - INDIA

  • WHO reported one laboratory-confirmed case of Nipah virus (NiV) infection on June 25, 2026, in an adult male in Kozhikode district, Kerala State, India, who developed neurological symptoms and was hospitalized June 10, 2026.
  • Kozhikode, Kerala, has been the epicenter of prior NiV spillover events from fruit bats (Pteropus medius); NiV carries a case fatality ratio of 40-75% and has no licensed treatment.

AVIAN INFLUENZA H9N2 - ITALY

  • WHO reported on April 10, 2026, a human H9N2 case in an adult male in Italy who had returned from Senegal; next-generation sequencing confirmed Influenza A(H9N2).
  • H9N2 is an enzootic avian influenza strain circulating widely in poultry in Africa and Asia; human cases are rare but the virus has donated internal gene segments to highly pathogenic H5N1 and H7N9 strains.

MEASLES - BANGLADESH

  • WHO notified on April 23, 2026, of a nationwide measles surge in Bangladesh, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported a combined 79 human yellow fever infections; WHO noted sustained transmission in the Americas following increased 2025 activity.

WEST NILE VIRUS - UNITED STATES

  • CDC on July 1, 2026, warned of an early West Nile season with record case counts, urging mosquito-bite prevention over the Independence Day holiday weekend.

🧬 LONGEVITY & AGING

STATIN DEPRESCRIBING IN ADULTS 75-PLUS

  • The SAGA/SITE multicentre, open-label, non-inferiority randomised trial published in Lancet Healthy Longevity examined discontinuation of statins for primary cardiovascular prevention in adults aged 75 or older, led by Bonnet, Poulizac, Rousselot, and colleagues. [2]
  • A linked commentary by Arya Nezhad, Rastgou, and Nanna cautions that while the trial addresses an important deprescribing question, the conversation around statin cessation in older adults must change default assumptions carefully rather than apply blanket rules.

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY

  • The DEMFOS randomised controlled trial published in Lancet Healthy Longevity by Nava, Viola, Aguilar, Bryant, Nambi, Armamento-Villareal, Qualls, and Villareal evaluated metformin added to lifestyle intervention specifically targeting physical function outcomes in older obese adults. [3]
  • A linked editorial by Witham and McDonald warns against inflated expectations, noting that metformin's benefits for frailty and obesity in older people require careful interpretation of effect sizes.
  • Deprescribing trials more broadly need a rationale-first framework before selecting trial design, according to two simultaneous Lancet Healthy Longevity letters by Hwang, Boockvar, Steinman and by Van der Linden.

SENESCENCE AND OSTEOARTHRITIS

  • A study in Bioactive Materials (An, Cai, Wu et al.) describes a dual-modal antioxidant plus epigenetic synergy strategy that attenuates the self-perpetuating senescence cycle specifically in osteoarthritis tissue, potentially interrupting the vicious cycle by which senescent chondrocytes recruit more senescent neighbors.

SENILE OSTEOPOROSIS AND STEM CELL SENESCENCE

  • Punicalagin, a polyphenol compound derived from pomegranate, was shown by Wang, Qin, Wang et al. to alleviate senile osteoporosis in a study published in Regenerative Therapy by inhibiting senescence of bone mesenchymal stem cells via the NRF2/HO-1 antioxidant pathway.

LYSOSOMAL AMPK AND LIVER DISEASE

  • Zhu, Sun, Wei et al. published in Bioactive Materials a study showing that targeting the protein ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASH) in a preclinical model — relevant because AMPK activation is a core pathway of both metabolic health and longevity biology.

TELOMERE REPAIR AND CANCER CELL SENESCENCE

  • Salmina, Rumnieks, Pjanova, Vainshelbaum, and Erenpreisa published in Nucleus a study on repair and misrepair of telomeric DNA in dynamic interactions with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells — providing mechanistic detail on how chemotherapy stress triggers senescent-like states via telomere damage.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • Lääti, Teppo, Vire, Viitanen, and Langén published in Blood Pressure a study using two Finnish generational cohorts born 20 years apart showing that positive life orientation is associated with lower blood pressure in older adults — a psychosocial longevity signal with biological plausibility through autonomic and neuroendocrine pathways.

P16-INK4A DETECTION IN SENESCENCE RESEARCH

  • Pipella and Thompson published in Islets a methodological study emphasising the critical importance of antibody validation when detecting p16-INK4A, the canonical cell cycle inhibitor and senescence marker, by immunohistochemistry on pancreas tissue — a practical note for the field given how frequently p16 misdetection skews senescence studies.

CANINE EPIGENETIC AGING AND DIET

  • Chen, Guo, Krumbeck, Su, Michels, and Yang published in Veterinary Record Open a pilot study showing that a minimally processed, human-grade diet altered canine epigenetic aging clocks — adding to cross-species evidence that dietary quality modulates biological age independent of caloric intake.

💊 NEW CURES & APPROVALS

METFORMIN HYDROCHLORIDE - MULTIPLE MANUFACTURERS, SUPPLEMENTAL APPROVALS

  • FDA supplemental approvals recorded for Metformin Hydrochloride from Zydus Healthcare (ANDA203686), BionPharma (ANDA219151), Torrent Pharmaceuticals Ltd (ANDA079226), Torrent Pharmaceuticals (ANDA077711), Sunshine (ANDA208999), Yichang Humanwell (ANDA211052), and Novast Labs (ANDA209674), indicating manufacturing or labeling updates across the generic landscape for this Type 2 diabetes and longevity-investigated agent.

XIGDUO XR (DAPAGLIFLOZIN/METFORMIN HCl) - ASTRAZENECA AB, SUPPLEMENTAL APPROVAL

  • AstraZeneca AB received a supplemental approval for Xigduo XR (NDA205649), the fixed-dose combination SGLT2 inhibitor dapagliflozin plus metformin HCl, approved for Type 2 diabetes management.

SYNJARDY XR (EMPAGLIFLOZIN/METFORMIN HCl) - BOEHRINGER INGELHEIM, SUPPLEMENTAL APPROVAL

  • Boehringer Ingelheim received a supplemental approval for Synjardy XR (NDA208658), the fixed-dose combination SGLT2 inhibitor empagliflozin plus metformin HCl, approved for Type 2 diabetes; empagliflozin carries a proven cardiovascular mortality benefit in the EMPA-REG OUTCOME trial.

OPDIVO (NIVOLUMAB) - BRISTOL MYERS SQUIBB, SUPPLEMENTAL APPROVAL

  • Bristol Myers Squibb received a supplemental approval for Opdivo (BLA125554), the PD-1 checkpoint inhibitor nivolumab, with the specific new indication not specified in the filing summary beyond the supplemental action.

WINREVAIR (SOTATERCEPT-CSRK) - MERCK SHARP DOHME, SUPPLEMENTAL APPROVAL

  • Merck Sharp Dohme received a supplemental approval for Winrevair (BLA761363), sotatercept-csrk, the activin receptor signaling inhibitor originally approved for pulmonary arterial hypertension (PAH); this supplemental action may reflect a label expansion or updated safety data.

FOSFOMYCIN TROMETHAMINE - NOVITIUM PHARMA, ORIGINAL APPROVAL

  • Novitium Pharma received an original (new) approval for Fosfomycin Tromethamine (ANDA210426), an antibiotic active against uncomplicated lower urinary tract infections, including multidrug-resistant strains of E. coli.

HEPZATO (MELPHALAN HYDROCHLORIDE) - DELCATH SYSTEMS INC, SUPPLEMENTAL APPROVAL

  • Delcath Systems Inc. received a supplemental approval for Hepzato (NDA201848), melphalan hydrochloride for use via hepatic delivery, approved for metastatic uveal melanoma with unresectable hepatic metastases.

DUREZOL (DIFLUPREDNATE) - SANDOZ, SUPPLEMENTAL APPROVAL

  • Sandoz received a supplemental approval for Durezol (NDA022212), difluprednate ophthalmic emulsion, a corticosteroid indicated for inflammation and pain after ocular surgery.

🧪 CLINICAL TRIALS

MK-2214 FOR EARLY ALZHEIMER'S DISEASE - MERCK, PHASE UNSPECIFIED (NCT07033494)

  • A study of MK-2214 in people with early Alzheimer's disease (protocol MK-2214-004) opened on ClinicalTrials.gov as of August 14, 2026; the trial aims to determine whether MK-2214 slows brain changes in AD, specifically targeting memory, communication, and decision-making decline.
  • Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4, NCT05617014), a non-randomized longitudinal natural history study, continues to validate biomarkers and improve clinical trial design across the full AD disease spectrum.

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID (PD1-PASC I) - PHASE I (NCT07388550)

  • A Phase I open-label safety trial at ClinicalTrials.gov is testing pembrolizumab (a PD-1 checkpoint inhibitor) for neurological post-acute sequelae of SARS-CoV-2, including persistent headache, loss of taste/smell, dizziness, and gait problems; the mechanism hypothesis is that PD-1 blockade may clear viral antigen reservoirs driving neuroinflammation.

COMPREHENSIVE KIDNEY FUNCTION ASSESSMENT IN OLDER CHINESE ADULTS (NCT07765134)

  • A completed observational cohort study evaluating clinical and molecular markers of kidney function — including glomerular filtration, tubular transport, and kidney endocrine function — in two cohorts of Chinese adults aged 60 years or older, aiming to build early warning tools for kidney aging.

EXERCISE DURING CHEMOTHERAPY IN OLDER WOMEN WITH BREAST CANCER (NCT05025059)

  • A feasibility clinical trial evaluates exercise programs during chemotherapy in older women with Stage I-III breast cancer, testing whether physical activity can reduce chemotherapy-related toxicity in an aging oncology population.

TELEHEALTH FALL PREVENTION IN OLDER ADULTS (EGAPCARE) - NCT07034287

  • A clinical trial is testing eGAPcare, a telehealth modification of the GAPcare fall prevention program, using remote physical therapy and pharmacy consultation in older adults presenting to a community emergency department.

SAT-3247 FOR DUCHENNE MUSCULAR DYSTROPHY - PHASE 2A (NCT07287189)

  • A Phase 2a randomized, double-blind, placebo-controlled trial of SAT-3247 in ambulatory Duchenne muscular dystrophy patients aged 7 to under 10 years is enrolling; Part 1 tests two doses over 12 weeks to determine optimal dose, safety, and tolerability.

ELECTROACUPUNCTURE PLUS AURICULAR ACUPRESSURE FOR CHRONIC LOW BACK PAIN (NCT07530042)

  • A clinical trial evaluating the combination of electroacupuncture (EA) and auricular acupressure (AA) for chronic low back pain due to lumbar spondylosis in middle-aged and elderly populations is recruiting on ClinicalTrials.gov.

📢 PUBLIC HEALTH

CDC SALMONELLA ALERT - TINY TURTLES SOLD ILLEGALLY AS PETS

  • CDC issued an investigation notice on August 16, 2026, warning that tiny turtles — illegal to sell as pets in the U.S. under a 1975 FDA regulation due to Salmonella risk — are again causing Salmonella illnesses in young children.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste as malaria-free on July 24, 2025, marking a major elimination milestone for a country that launched a nationwide response shortly after gaining independence in 2002.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES 1 MILLION PARTICIPANTS

  • CDC announced on January 30, 2026, that its Traveler-Based Genomic Surveillance program exceeded one million voluntary air travel participants, strengthening real-time detection of emerging pathogen variants at U.S. ports of entry.

U.S. COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 failures and organizational politicization; WHO expressed regret, stating the decision makes both the U.S. and the world less safe.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, reflecting concern about this parasitic fly's potential spread as a One Health threat to livestock and humans in the U.S.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Discontinuation of statins for primary prevention of atheroscl… — Europe PMC — Longevity
  3. Metformin added to lifestyle intervention for physical functio… — Europe PMC — Longevity
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  9. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260816-02-v57 · 2026-08-16 02:02 UTC · pulse.uzylab.com

Read next